• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up.

作者信息

Horne Anne M, Mihov Borislav, Reid Ian R

机构信息

Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand.

Department of Endocrinology, Auckland District Health Board, Auckland, New Zealand.

出版信息

Calcif Tissue Int. 2019 Jul;105(1):107-108. doi: 10.1007/s00223-019-00553-w. Epub 2019 Apr 17.

DOI:10.1007/s00223-019-00553-w
PMID:31087124
Abstract
摘要

相似文献

1
Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up.唑来膦酸对罗莫单抗/地诺单抗治疗后骨质流失的影响：2年随访
Calcif Tissue Int. 2019 Jul;105(1):107-108. doi: 10.1007/s00223-019-00553-w. Epub 2019 Apr 17.
2
Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates.唑来膦酸/地舒单抗治疗后骨丢失：双膦酸盐的作用。
Calcif Tissue Int. 2018 Jul;103(1):55-61. doi: 10.1007/s00223-018-0404-6. Epub 2018 Feb 14.
3
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.唑来膦酸预防停用地舒单抗治疗的女性骨丢失：一项前瞻性 2 年临床试验。
J Bone Miner Res. 2019 Dec;34(12):2220-2228. doi: 10.1002/jbmr.3853. Epub 2019 Oct 14.
4
Zoledronate Slows Weight Loss and Maintains Fat Mass in Osteopenic Older Women: Secondary Analysis of a Randomized Controlled Trial.唑来膦酸可减缓骨质疏松老年女性体重减轻并维持脂肪量：一项随机对照试验的二次分析。
Calcif Tissue Int. 2020 Apr;106(4):386-391. doi: 10.1007/s00223-019-00653-7. Epub 2020 Jan 2.
5
In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.地诺单抗对骨巨细胞瘤影响的体外研究：与唑来膦酸的比较
Pathol Oncol Res. 2019 Jan;25(1):409-419. doi: 10.1007/s12253-017-0362-8. Epub 2017 Nov 20.
6
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.罗莫佐单抗治疗 24 个月后序贯地舒单抗或安慰剂治疗 12 个月对骨密度低的绝经后妇女的影响：一项随机、双盲、2 期、平行组研究。
J Bone Miner Res. 2018 Aug;33(8):1397-1406. doi: 10.1002/jbmr.3452. Epub 2018 May 22.
7
One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.罗莫佐单抗治疗 1 年后序贯地舒单抗治疗 2 年可维持骨折风险降低：FRAME 扩展研究结果。
J Bone Miner Res. 2019 Mar;34(3):419-428. doi: 10.1002/jbmr.3622. Epub 2018 Dec 3.
8
Zoledronic Acid Improves Bone Quality in the Streptozotocin-Induced Diabetes Rat through Affecting the Expression of the Osteoblast-Regulating Transcription Factors.唑来膦酸通过影响成骨细胞调节转录因子的表达改善链脲佐菌素诱导的糖尿病大鼠的骨质量。
Exp Clin Endocrinol Diabetes. 2019 Jan;127(1):68-75. doi: 10.1055/s-0042-105282. Epub 2016 Jun 29.
9
Romosozumab (Evenity) for postmenopausal osteoporosis.罗莫单抗（艾地骨化醇）用于绝经后骨质疏松症。
Med Lett Drugs Ther. 2019 Jun 3;61(1573):83-86.
10
Molecule of the Month. Denosumab.本月分子。地诺单抗。
Drug News Perspect. 2009 Jul-Aug;22(6):356. doi: 10.1358/dnp.2009.22.6.1398716.

引用本文的文献

1
The 2024 UK clinical guideline for the prevention and treatment of osteoporosis.《2024年英国骨质疏松症防治临床指南》
Arch Osteoporos. 2025 Sep 8;20(1):119. doi: 10.1007/s11657-025-01588-3.
2
Response to the Letter to the Editor regarding "The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland" by Yang and colleagues.对Yang及其同事发表的《关于“罗莫单抗对骨密度的影响取决于既往治疗：瑞士一项前瞻性、多中心队列研究”致编辑的信》的回复。
Osteoporos Int. 2025 Feb;36(2):343-344. doi: 10.1007/s00198-024-07282-3. Epub 2024 Oct 28.
3
[Osteoporosis-Definition, risk assessment, diagnosis, prevention and treatment (update 2024) : Guidelines of the Austrian Society for Bone and Mineral Research].
[骨质疏松症——定义、风险评估、诊断、预防与治疗（2024年更新版）：奥地利骨与矿物质研究学会指南]
Wien Klin Wochenschr. 2024 Oct;136(Suppl 16):599-668. doi: 10.1007/s00508-024-02441-2. Epub 2024 Oct 2.
4
The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial.地舒单抗（CARD）研究后阿仑膦酸钠和雷洛昔芬的比较：一项比较疗效试验。
Osteoporos Int. 2024 Feb;35(2):255-263. doi: 10.1007/s00198-023-06932-2. Epub 2023 Oct 6.
5
Discontinuation of Denosumab: Gradual Decrease in Doses Preserves Half of the Bone Mineral Density Gain at the Lumbar Spine.地诺单抗停药：逐渐减少剂量可保留腰椎骨密度增加量的一半。
JBMR Plus. 2023 May 18;7(7):e10731. doi: 10.1002/jbm4.10731. eCollection 2023 Jul.
6
The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence.骨质疏松症序贯和联合治疗的理由和方法。对当前证据的回顾。
Arch Endocrinol Metab. 2022 Nov 11;66(5):724-738. doi: 10.20945/2359-3997000000564.
7
The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA-HD Study Extension.唑来膦酸对地舒单抗和特立帕肽治疗后骨微结构和骨强度的影响：DATA-HD 研究扩展。
J Bone Miner Res. 2023 Jan;38(1):26-34. doi: 10.1002/jbmr.4737. Epub 2022 Nov 23.
8
UK clinical guideline for the prevention and treatment of osteoporosis.英国临床骨质疏松症预防和治疗指南。
Arch Osteoporos. 2022 Apr 5;17(1):58. doi: 10.1007/s11657-022-01061-5.
9
Osteoporosis in 10 years time: a glimpse into the future of osteoporosis.十年后的骨质疏松症：展望骨质疏松症的未来
Ther Adv Musculoskelet Dis. 2022 Mar 20;14:1759720X221083541. doi: 10.1177/1759720X221083541. eCollection 2022.
10
Should denosumab treatment for osteoporosis be continued indefinitely?治疗骨质疏松症的地诺单抗疗法是否应无限期持续？
Ther Adv Endocrinol Metab. 2021 Apr 22;12:20420188211010052. doi: 10.1177/20420188211010052. eCollection 2021.